Biotech Values

[DewDiligence]

>I like REGN's efficacy data and the fact that REGN might include Lucentis as control arm in P3.<

As previously posted (#msg-10907088), I thought the VEGF-Trap phase-1 data were impressive for an evaluation six weeks after a single treatment. What I find baffling is that SNY had no interest in pursuing VEGF-Trap in ophthalmology despite having paid big money in 2003 to acquire the rights in all indications.